Furthermore, the CREDENCE trial and the DAPA-CKD trial evaluated the efficacy of SGLT2 inhibitor therapy in patients with CKD, with and without Type 2 diabetes [84,85]. The gene discussed is SLC5A2; the disease is chronic kidney disease.